For example, TFAP2A has been reported to reduce the expression of CRTAC1 by promoting TPRG1-AS1 transcription, thereby accelerating glycolysis and angiogenesis in bladder urothelial carcinoma (BLCA) and promoting the progression of BLCA [8]. Here, TFAP2A is linked to bladder transitional cell carcinoma.